Myelodysplastic Syndrome Treated by Integrated Chinese and Western Medicine: A Case Report.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: InnoVision Communications Country of Publication: United States NLM ID: 9502013 Publication Model: Print Cited Medium: Print ISSN: 1078-6791 (Print) Linking ISSN: 10786791 NLM ISO Abbreviation: Altern Ther Health Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: Aliso Viejo, CA : InnoVision Communications, c1995-
    • Subject Terms:
      Myelodysplastic Syndromes*/drug therapy; Aged ; Female ; Humans ; Male ; Middle Aged ; Asian People ; Azacitidine/therapeutic use ; Leukemia/prevention & control ; Programmed Cell Death 1 Receptor ; China
    • Abstract:
      Context: Myelodysplastic syndrome (MDS) is a group of highly heterogeneous, malignant clonal diseases derived from hematopoietic stem cells. PD-1 monoclonal antibodies can have a synergistic effect with hypomethylating agents (HMAs), especially for patients with drug resistance to demethylation drugs. TCM in the treatment of MDS can improve hematological indexes, and for some patients, control the proliferation of primitive cells and delay or even block the transformation to leukemia.
      Objective: The study intended to examine the therapeutic effects of programmed cell death-1 (PD-1) inhibitors and azacitidine combined with the Yisuifang Thick Decoction in the treatment of MDS with older, high-risk patients.
      Design: The research team performed five prospective case studies.
      Setting: The study took place at the East Hospital affiliated with Beijing University of Chinese Medicine in Beijing, China.
      Participants: Participants were five older, high-risk MDS patients at the hospital who received PD-1 and azacitidine combined with Yisuifang Thick Decoction between April 2020 and June 2021.
      Outcome Measures: The research team measured: (1) treatment duration, (2) curative effects, (3) myelosuppression, (4) immune-related adverse reactions, (5) ending outcomes, and (6) progression-free survival (PFS).
      Results: The male to female ratio for the five participants was 3:2, and the median age was 69 years, with a range from 62 to 79 years. Four participants had refractory HR-MDS and one had primary MDS. The median treatment duration was 3 months, with a range from 2 to 4 months, and the median progression-free survival (PFS) was 5 months, with a range from 3 to 14 months. All participants achieved a partial response (PR) or a complete remission with incomplete count recovery (CRi) and showed improvement in serological indexes.
      Conclusions: Older, high-risk MDS patients generally have poor physical conditions, often accompanied by a poor karyotype prognosis and a poor prognosis for survival. Therefore, the combination of PD-1, azacytidine, and Yisuifang Thick Decoction may be an effective way to treat HR-MDS.
    • Accession Number:
      M801H13NRU (Azacitidine)
      0 (Programmed Cell Death 1 Receptor)
    • Publication Date:
      Date Created: 20230609 Date Completed: 20230905 Latest Revision: 20230905
    • Publication Date:
      20240829
    • Accession Number:
      37295013